Pilabactam sodium clinical trials
Also written ANT3310.
A product of Pilabactam; its studies count on that page too.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2023
How each study uses pilabactam sodium is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- ANT3310
- 3
Studies by the year they started
3 studies that test it; most in 2023 (1)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
Who runs them
Industry 3 · Other 0
Antabio (3)
Related medicines
As reviewed, each with the page that says it.
- A salt or form of Pilabactam
Studies
Open first, then newest update. How each study uses pilabactam sodium is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Evaluation of the Concentration of ANT3310 and Meropenem in the Lung in Healthy Adult ParticipantsCompletedPhase 1AntabioNCT06916156Written as ANT3310
- Assessment of the Pharmacokinetics and Safety of ANT3310 Combined With Meropenem in Renally Impaired SubjectsCompletedPhase 1AntabioNCT06527677Written as ANT3310
- FiH Study to Assess Safety and PK of SAD and MAD of ANT3310 Alone and in Combination With Meropenem in Healthy SubjectsCompletedPhase 1AntabioNCT05905913Written as ANT3310